Telix Progresses Novel Lung and Ovarian Cancer Theranostic APOMAB®
Telix extends partnership with AusHealth relating to APOMAB®, a novel theranostic being investigated in lung and ovarian cancers
Telix’s TLX66 in Phase II Academic Study of Pediatric Leukemia
Telix announces Phase II academic study of TLX66 in children with high-risk leukemia.
Telix H1 2021 Results and Company Update Conference Call
Telix to hold investor conference call to present H1 2021 financial results and Company update.
Mr. Ryoichi Tanaka Joins Telix Japan as Chief Operating Officer
Telix is delighted to announce that Ryoichi Tanaka has joined the Japan business as Chief Operating Officer and Head of Business Development.
First Patient Dosed in CUPID Study of Telix’s Targeted Alpha Therapy Candidate for Prostate Cancer
Telix announces the first patient has been dosed in its ‘CUPID’ Phase I study of TLX592 in patients with advanced prostate cancer.
Ms. Helen Hovenga Joins Telix as Chief People Officer
Telix is delighted to announce that Ms. Helen Hovenga has joined the Telix executive team in the role of Chief People Officer.
Telix Seneffe Production Facility: Progress Update
Telix authorised to decommission first of two cyclotrons at Seneffe radiopharmaceutical production facility.
Activities Report and Appendix 4C for June 2021 Quarter
Telix provides its Appendix 4C and accompanying Activities Report for the quarter ended 30 June 2021.
ZIRCON Phase 3 Renal Cancer Imaging Study: Progress Update
Progress update on the ZIRCON Phase 3 study for the imaging of renal cancer with Positron Emission Tomography (PET).
Telix Appoints Gabrielle Wermenbol as Chief Financial Officer, EMEA
Telix is delighted to announce the appointment of Gabrielle Wermenbol as Chief Financial Officer, Europe, Middle East and Africa (EMEA).